ASA, aminosalicylic acid; IV, intravenous; n, number of patients; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis.

^a21 patients were excluded from the evaluable population due to violation of the selection criteria.

^bPatients were enrolled at 244 sites from 33 countries in nine regions: Western Europe [Austria, France, Germany], Eastern Europe [Bulgaria, Czech Republic, Romania, Russia, Slovakia, Ukraine], Northern Europe [Estonia, Ireland, Sweden, UK], Southern Europe [Bosnia and Herzegovina, Croatia, Greece, Italy, Portugal, Serbia, Slovenia, Spain], Canada [Canada], Western Asia [Israel, Kuwait, Turkey, Saudi Arabia], Africa [Egypt, South Africa], Latin America [Argentina, Chile, Colombia, Mexico], Japan [Japan].

^cTime since UC diagnosis (calculated as difference between date of UC diagnosis and visit date, days). The 15th day was used as the default diagnosis date; therefore, negative values can occur. All patients included in the study had a confirmed UC diagnosis before Visit 1 (baseline visit).

^d  n-values combined within each class of medication.

^eCaptured by the physician; possible answers on the case report form included previously diagnosed with: ankylosing spondylitis, erythema nodosum, hidradenitis suppurativa, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, pyoderma gangrenosum, rheumatoid arthritis, uveitis, other, or ‘the patient has not been reported to have any extra-intestinal manifestation’.

^fCaptured by the physician; possible answers on the case report form included anxiety/depression, any malignancies, cardiac abnormalities/cardiovascular disease, chronic renal disease or insufficiency, chronic pulmonary disease, cognitive dysfunction, diabetes mellitus, fatigue, low body weight <20 body mass index, polyneuropathy/neuropathy, postural hypotension, skin disease, and sleep disorders.